Albert Einstein Medical Center, Philadelphia, PA.
Willes Consulting Group, Inc, Encinitas, CA.
Chest. 2020 Sep;158(3):1198-1207. doi: 10.1016/j.chest.2020.03.036. Epub 2020 Apr 2.
COPD is the second most common cause of hospital admission in the United States. OSA is a highly prevalent and underdiagnosed condition that may affect the outcome of COPD.
We hypothesized that presence of unrecognized and untreated OSA will increase hospital readmissions in patients admitted for COPD exacerbation.
We reviewed patients admitted for COPD exacerbation from May 2017 through July 2018 who were also screened for previously unrecognized and untreated OSA with a sleep questionnaire, and who subsequently underwent a high-resolution pulse oximetry or portable sleep monitoring study. We compared the rates of 30-, 90-, and 180-day readmission or death across OSA categories and compared overall survival in patients with and without OSA.
Of 380 patients admitted for COPD exacerbation, 256 were screened for OSA with a sleep questionnaire (snoring, tiredness during daytime, observed apnea, high BP). Of these, 238 underwent an overnight high-resolution pulse oximetry/portable sleep monitoring. Of the 238 total patients, 111 (46.6%) were found to have OSA; 28.6% had mild, 9.7% moderate, and 8.4% severe OSA. Baseline characteristics and demographics were compared between the cohorts of participants with OSA and without OSA and were similar except that patients with OSA had a higher mean BMI (33.9 vs 30.3 kg/m) and an increased prevalence of heart failure (19.8% vs 7.1%). For patients with COPD and mild OSA, odds of 30-day readmission were 2.05 times higher than for patients without OSA (32.4% vs 18.9%). Additionally, odds of 30-day readmission were 6.68 times higher for patients with moderate OSA vs patients without OSA (60.9% vs 18.9%) and 10.01 times high for patients with severe OSA vs patients without OSA (70% vs 18.9%). Readmission rates were also greater at 90 and 180 days. All-cause mortality was lower for patients without OSA than for patients with OSA (P < .01). The time to hospital readmission or death was shorter with greater OSA severity (P < .01).
Patients hospitalized for COPD exacerbation and who have unrecognized OSA; 30-, 90-, and 180-day readmission rates; and 6-month mortality rates are higher than in those without OSA.
在美国,COPD 是第二大常见的住院原因。OSA 是一种高度普遍但未被充分诊断的疾病,可能会影响 COPD 的预后。
我们假设,对于因 COPD 加重而入院的患者,如果存在未经识别和未经治疗的 OSA,将会增加其住院再入院率。
我们回顾了 2017 年 5 月至 2018 年 7 月期间因 COPD 加重而入院的患者,这些患者还接受了睡眠问卷筛查,以发现以前未被识别和未经治疗的 OSA,并随后接受了高分辨率脉搏血氧仪或便携式睡眠监测研究。我们比较了 OSA 各分类组在 30、90 和 180 天的再入院或死亡率,并比较了有和无 OSA 患者的总体生存率。
在因 COPD 加重而入院的 380 名患者中,有 256 名患者接受了睡眠问卷筛查 OSA(打鼾、白天嗜睡、观察到的呼吸暂停、高血压)。其中,238 名患者接受了一夜的高分辨率脉搏血氧仪/便携式睡眠监测。在 238 名患者中,有 111 名(46.6%)患有 OSA;28.6%为轻度、9.7%为中度、8.4%为重度。在有 OSA 和无 OSA 的患者队列之间比较了基线特征和人口统计学特征,除了 OSA 患者的平均 BMI(33.9 比 30.3 kg/m2)更高和心力衰竭的发生率(19.8%比 7.1%)更高外,这些特征和特征都相似。对于患有 COPD 和轻度 OSA 的患者,30 天再入院的几率是无 OSA 患者的 2.05 倍(32.4%比 18.9%)。此外,中度 OSA 患者 30 天再入院的几率是无 OSA 患者的 6.68 倍(60.9%比 18.9%),重度 OSA 患者是无 OSA 患者的 10.01 倍(70%比 18.9%)。90 天和 180 天的再入院率也更高。无 OSA 患者的全因死亡率低于有 OSA 患者(P<.01)。OSA 严重程度越高,住院再入院或死亡的时间越短(P<.01)。